Binding of [3H]dihydroazapetine to alpha-adrenoreceptor-related proteins from rat vas deferens
- PMID: 8779
- PMCID: PMC430722
- DOI: 10.1073/pnas.73.8.2730
Binding of [3H]dihydroazapetine to alpha-adrenoreceptor-related proteins from rat vas deferens
Abstract
The potent alpha-adrenoreceptor blocking agent, azapetine, has been catalytically reduced with tritium gas to form [3H]dihydroazapetine. [3H]Dihydroazapetine retains significant ability to block alpha-adrenoreceptors and has been used as a ligand to study the receptor in a subcellular fraction containing membrane fragments from rat vas deferens. Specific binding of [3H]dihydroazapetine rapidly reaches equilibrium and is also reversible and saturable with a dissociation constant similar to that determined pharmacologically. The binding capacity is approximately 40 pmol/mg of protein. All alpha-adrenergic blockers tested were able to inhibit specific binding. High concentrations of alprenolol, atropine, or chlorpheniramine had no effect. In addition, all alpha-adrenergic agonists of the imidazoline class inhibit binding in low concentrations, whereas soterenol or carbamylcholine did not. There is good correlation (r=0.84) between blockade or stimulation of the receptor in intact tissues and inhibition of binding of [3H]dihydroazapetine to the subcellular fraction. These findings suggest that the fraction contains alpha-adrenoreceptor-related proteins. Alpha-adrenergic agonists structurally related to norepinephrine caused a stereoselective increase in binding in favor of the (-)-isomer, possibly reflecting an allosteric interaction at a different binding site on the receptor protein. The possibility of two different modes of binding for structurally dissimilar agonists is suggested.
Similar articles
-
Further biochemical characterization of [3H]dihydroazapetine binding to alpha-adrenoceptorrelated proteins from the rat vas deferens.J Pharm Pharmacol. 1978 Aug;30(8):498-502. doi: 10.1111/j.2042-7158.1978.tb13302.x. J Pharm Pharmacol. 1978. PMID: 28398 No abstract available.
-
Kinetics of accumulation, efflux and the pharmacological effects of tritiated dihydroazapetine on the rabbit aorta.J Pharmacol Exp Ther. 1977 Aug;202(2):278-86. J Pharmacol Exp Ther. 1977. PMID: 18596
-
Occupancy of alpha 1-adrenergic receptors and contraction of rat vas deferens.Mol Pharmacol. 1983 Mar;23(2):359-68. Mol Pharmacol. 1983. PMID: 6300645
-
"Spare" alpha 1-adrenergic receptors and the potency of agonists in rat vas deferens.Mol Pharmacol. 1984 Jan;25(1):56-63. Mol Pharmacol. 1984. PMID: 6143249
-
Mechanisms of facilitation and muscarinic or alpha-adrenergic inhibition of acetylcholine and noradrenaline secretion from peripheral nerves.Acta Physiol Scand Suppl. 1982;506:1-39. Acta Physiol Scand Suppl. 1982. PMID: 6293252 Review.
Cited by
-
Neurochemical evidence for two types of presynaptic alpha 2-adrenoceptors.Neurochem Res. 1987 Feb;12(2):141-7. doi: 10.1007/BF00979530. Neurochem Res. 1987. PMID: 3033532
-
I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.Drugs Aging. 2000 Aug;17(2):133-59. doi: 10.2165/00002512-200017020-00005. Drugs Aging. 2000. PMID: 10984201 Review.
-
Biphasic adrenergic modulation of beta-adrenergic receptors in man. Agonist-induced early increment and late decrement in beta-adrenergic receptor number.J Clin Invest. 1980 Apr;65(4):836-40. doi: 10.1172/JCI109735. J Clin Invest. 1980. PMID: 6102098 Free PMC article.
-
Characterization of the human platelet alpha-adrenergic receptor. Correlation of [3H]dihydroergocryptine binding with aggregation and adenylate cyclase inhibition.J Clin Invest. 1978 May;61(5):1136-44. doi: 10.1172/JCI109028. J Clin Invest. 1978. PMID: 207726 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources